{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:29:06Z","timestamp":1774268946712,"version":"3.50.1"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T00:00:00Z","timestamp":1438214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0134308","type":"journal-article","created":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T17:59:05Z","timestamp":1438279145000},"page":"e0134308","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice"],"prefix":"10.1371","volume":"10","author":[{"given":"Dong Hyun","family":"Jo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Wook","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Sik","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Powner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Hyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Fruttiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Hun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,7,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajpath.2012.06.006","article-title":"A brief history of anti-VEGF for the treatment of ocular angiogenesis","volume":"181","author":"LA Kim","year":"2012","journal-title":"Am J Pathol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s12272-013-0324-y","article-title":"Allosteric regulation of pathologic angiogenesis: potential application for angiogenesis-related blindness","volume":"37","author":"DH Jo","year":"2014","journal-title":"Arch Pharm Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"HA Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jaapos.2011.11.002","article-title":"Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both?","volume":"16","author":"RL Avery","year":"2012","journal-title":"J AAPOS"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"A Hellstrom","year":"2013","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"DF Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","article-title":"On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment\u2014a review","volume":"100","author":"AL Hard","year":"2011","journal-title":"Acta Paediatr"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/eye.2012.111","article-title":"Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity","volume":"26","author":"BJ Lee","year":"2012","journal-title":"Eye (Lond)"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings","volume":"121","author":"D Lepore","year":"2014","journal-title":"Ophthalmology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","article-title":"Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease","volume":"56","author":"M Tolentino","year":"2011","journal-title":"Surv Ophthalmol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1167\/iovs.13-12574","article-title":"Expression of neonatal Fc receptor in the eye","volume":"55","author":"MB Powner","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref12","first-page":"2803","article-title":"FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye","volume":"15","author":"H Kim","year":"2009","journal-title":"Mol Vis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1096\/fj.12-221812","article-title":"Vascular endothelial growth factor is important for brown adipose tissue development and maintenance","volume":"27","author":"M Bagchi","year":"2013","journal-title":"FASEB J"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1172\/JCI32239","article-title":"Angiogenesis modulates adipogenesis and obesity","volume":"117","author":"Y Cao","year":"2007","journal-title":"J Clin Invest"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1172\/JCI71643","article-title":"Vascular rarefaction mediates whitening of brown fat in obesity","volume":"124","author":"I Shimizu","year":"2014","journal-title":"J Clin Invest"},{"key":"ref16","first-page":"101","article-title":"Oxygen-induced retinopathy in the mouse","volume":"35","author":"LE Smith","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/j.1582-4934.2008.00243.x","article-title":"Deguelin inhibits retinal neovascularization by down-regulation of HIF-1alpha in oxygen-induced retinopathy","volume":"12","author":"JH Kim","year":"2008","journal-title":"J Cell Mol Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jaapos.2009.12.002","article-title":"Avastin as monotherapy for retinopathy of prematurity","volume":"14","author":"HA Mintz-Hittner","year":"2010","journal-title":"J AAPOS"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1695.e1","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"RL Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1167\/iovs.09-4140","article-title":"Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes","volume":"51","author":"T Miyake","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1167\/iovs.09-4425","article-title":"Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes","volume":"51","author":"WC Wu","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref22","first-page":"161","article-title":"Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy","volume":"31","author":"J Qian","year":"2011","journal-title":"Retina"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"T Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/jama.293.12.1509","article-title":"Inhibitors of ocular neovascularization: promises and potential problems","volume":"293","author":"P van Wijngaarden","year":"2005","journal-title":"JAMA"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"9886","DOI":"10.1158\/0008-5472.CAN-10-1419","article-title":"Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model","volume":"70","author":"MO Stefanini","year":"2010","journal-title":"Cancer Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","article-title":"Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer","volume":"19","author":"MS Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.molmet.2014.03.010","article-title":"Brown adipose tissue derived VEGF-A modulates cold tolerance and energy expenditure","volume":"3","author":"K Sun","year":"2014","journal-title":"Mol Metab"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cmet.2012.12.010","article-title":"Adipose vascular endothelial growth factor regulates metabolic homeostasis through angiogenesis","volume":"17","author":"HK Sung","year":"2013","journal-title":"Cell Metab"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cmet.2008.11.009","article-title":"Hypoxia-independent angiogenesis in adipose tissues during cold acclimation","volume":"9","author":"Y Xue","year":"2009","journal-title":"Cell Metab"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/db11-0832","article-title":"Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance","volume":"61","author":"I Elias","year":"2012","journal-title":"Diabetes"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1152\/physrev.00015.2003","article-title":"Brown adipose tissue: function and physiological significance","volume":"84","author":"B Cannon","year":"2004","journal-title":"Physiol Rev"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1172\/JCI78362","article-title":"Brown and beige fat in humans: thermogenic adipocytes that control energy and glucose homeostasis","volume":"125","author":"L Sidossis","year":"2015","journal-title":"J Clin Invest"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.cmet.2014.07.025","article-title":"Brown fat in humans: consensus points and experimental guidelines","volume":"20","author":"AM Cypess","year":"2014","journal-title":"Cell Metab"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0134308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:25:46Z","timestamp":1588969546000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0134308"}},"subtitle":[],"editor":[{"given":"Mari\u00e0","family":"Alemany","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,7,30]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,7,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0134308","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,30]]}}}